Skip to main content
Top
Published in: Heart Failure Reviews 6/2020

01-11-2020 | Heart Failure

Does heart failure increase the risk of incident cancer? A meta-analysis and systematic review

Authors: Hanlai Zhang, Yonghong Gao, Liqin Wang, Li Tian, Na An, Xinyu Yang, Xinye Li, Chao Tian, Mengchen Yuan, Xingjiang Xiong, Nian Liu, Hongcai Shang, Yanwei Xing

Published in: Heart Failure Reviews | Issue 6/2020

Login to get access

Abstract

Recently, several studies have demonstrated that heart failure (HF) may increase the risk of incident cancer. However, this association has not been statistically and systematically verified by any comprehensive pooled analyses. We performed a meta-analysis on cancer morbidity and co-mortality of adults with HF in a large sample size to explore the relationship between HF and the risk of developing cancer. From inception to April 2019, we searched PubMed and EMBASE for published relevant articles on patients with HF diagnosed with cancer afterwards, with reported outcomes of morbidity and mortality. Two investigators independently reviewed these included studies. Study data were independently extracted using predefined data extraction forms. Random and fixed-effects models were fit for the study duration. This analysis consisted of 4 cohort studies comprising 5,004,251 participants. The relative risk (RR) for incident cancer was 1.22 (95% confidence interval (CI), 1.13–1.33) indicating that patients with HF may have a higher risk of developing cancer. The pooled RR of co-mortality was 2.03 (95% CI, 1.13–3.65), indicating that HF associated with cancer increases the risk of mortality. In this meta-analysis and systematic review, our results demonstrated that heart failure may increase the risk of incident cancer and that HF associated with cancer increases the risk of mortality.
Literature
1.
go back to reference Angsutararux P et al (2015) Chemotherapy-Induced cardiotoxicity: overview of the roles of oxidative stress. Oxidative Med Cell Longev 2015:795602CrossRef Angsutararux P et al (2015) Chemotherapy-Induced cardiotoxicity: overview of the roles of oxidative stress. Oxidative Med Cell Longev 2015:795602CrossRef
2.
go back to reference Balkwill F, Mantovani A (2010) Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther 87(4):401–406CrossRef Balkwill F, Mantovani A (2010) Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther 87(4):401–406CrossRef
3.
go back to reference Banke A et al (2016) Incidence of cancer in patients with chronic heart failure: a long-term follow-up study. Eur J Heart Fail 18(3):260–266CrossRef Banke A et al (2016) Incidence of cancer in patients with chronic heart failure: a long-term follow-up study. Eur J Heart Fail 18(3):260–266CrossRef
4.
go back to reference Blaes A et al (2017) Cardio-oncology related to heart failure: common risk factors between cancer and cardiovascular disease. Heart Fail Clin 13(2):367–380CrossRef Blaes A et al (2017) Cardio-oncology related to heart failure: common risk factors between cancer and cardiovascular disease. Heart Fail Clin 13(2):367–380CrossRef
5.
go back to reference De Bruijn KM et al (2013) Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br J Surg 100(11):1421–1429CrossRef De Bruijn KM et al (2013) Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br J Surg 100(11):1421–1429CrossRef
6.
go back to reference Deswal A, Basra SS (2013) Incident cancer in patients with heart failure: causation or mere association? J Am Coll Cardiol 62(10):887–888CrossRef Deswal A, Basra SS (2013) Incident cancer in patients with heart failure: causation or mere association? J Am Coll Cardiol 62(10):887–888CrossRef
7.
go back to reference Diakos CI et al (2014) Cancer-related inflammation and treatment effectiveness. Lancet Oncol 15(11):e493–e503CrossRef Diakos CI et al (2014) Cancer-related inflammation and treatment effectiveness. Lancet Oncol 15(11):e493–e503CrossRef
8.
go back to reference Dick SA, Epelman S (2016) Chronic heart failure and inflammation: what do we really know? Circ Res 119(1):159–176CrossRef Dick SA, Epelman S (2016) Chronic heart failure and inflammation: what do we really know? Circ Res 119(1):159–176CrossRef
9.
go back to reference Fung BM et al (2019) Cancer risk in primary sclerosing cholangitis: epidemiology, prevention, and surveillance strategies. World J Gastroenterol 25(6):659–671CrossRef Fung BM et al (2019) Cancer risk in primary sclerosing cholangitis: epidemiology, prevention, and surveillance strategies. World J Gastroenterol 25(6):659–671CrossRef
10.
go back to reference Gullestad L, Aukrust P (2005) Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am J Cardiol 95(11A):17C–23C discussion 38C-40CCrossRef Gullestad L, Aukrust P (2005) Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am J Cardiol 95(11A):17C–23C discussion 38C-40CCrossRef
11.
go back to reference Hasin T et al (2013) Patients with heart failure have an increased risk of incident cancer. J Am Coll Cardiol 62(10):881–886CrossRef Hasin T et al (2013) Patients with heart failure have an increased risk of incident cancer. J Am Coll Cardiol 62(10):881–886CrossRef
12.
go back to reference Hasin T et al (2016) Heart failure after myocardial infarction is associated with Increased risk of cancer. J Am Coll Cardiol 68(3):265–271CrossRef Hasin T et al (2016) Heart failure after myocardial infarction is associated with Increased risk of cancer. J Am Coll Cardiol 68(3):265–271CrossRef
13.
go back to reference Heidenreich PA et al (2013) Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6(3):606–619CrossRef Heidenreich PA et al (2013) Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6(3):606–619CrossRef
14.
go back to reference Hirsch FR et al (2017) Lung cancer: current therapies and new targeted treatments. Lancet 389(10066):299–311CrossRef Hirsch FR et al (2017) Lung cancer: current therapies and new targeted treatments. Lancet 389(10066):299–311CrossRef
15.
go back to reference Holden SE et al (2015) Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer. Diabetes Obes Metab 17(4):350–362CrossRef Holden SE et al (2015) Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer. Diabetes Obes Metab 17(4):350–362CrossRef
16.
go back to reference Hutton B et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777–784CrossRef Hutton B et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777–784CrossRef
17.
go back to reference Koene RJ et al (2016) Shared risk factors in cardiovascular disease and cancer. Circulation 133(11):1104–1114CrossRef Koene RJ et al (2016) Shared risk factors in cardiovascular disease and cancer. Circulation 133(11):1104–1114CrossRef
18.
go back to reference Libby P (2006) Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 83(2):456S–460SCrossRef Libby P (2006) Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 83(2):456S–460SCrossRef
19.
go back to reference Lin HC et al (2014) Effects of metformin dose on cancer risk reduction in patients with type 2 diabetes mellitus: a 6-year follow-up study. Pharmacotherapy 34(1):36–45CrossRef Lin HC et al (2014) Effects of metformin dose on cancer risk reduction in patients with type 2 diabetes mellitus: a 6-year follow-up study. Pharmacotherapy 34(1):36–45CrossRef
20.
go back to reference Lund LH et al (2014) Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction. Eur J Heart Fail 16(9):992–1001CrossRef Lund LH et al (2014) Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction. Eur J Heart Fail 16(9):992–1001CrossRef
21.
go back to reference Meijers WC et al (2018) Heart failure stimulates tumor growth by circulating factors. Circulation 138(7):678–691CrossRef Meijers WC et al (2018) Heart failure stimulates tumor growth by circulating factors. Circulation 138(7):678–691CrossRef
22.
go back to reference Murphy SL et al (2017) Deaths: final data for 2015. Natl Vital Stat Rep 66(6):1–75PubMed Murphy SL et al (2017) Deaths: final data for 2015. Natl Vital Stat Rep 66(6):1–75PubMed
23.
go back to reference Reina-Couto M et al (2014) Impaired resolution of inflammation in human chronic heart failure. Eur J Clin Investig 44(6):527–538CrossRef Reina-Couto M et al (2014) Impaired resolution of inflammation in human chronic heart failure. Eur J Clin Investig 44(6):527–538CrossRef
24.
go back to reference Selvaraj S et al (2018) Lack of association between heart failure and incident cancer. J Am Coll Cardiol 71(14):1501–1510CrossRef Selvaraj S et al (2018) Lack of association between heart failure and incident cancer. J Am Coll Cardiol 71(14):1501–1510CrossRef
25.
go back to reference Springer J et al (2014) Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. Eur Heart J 35(14):932–941CrossRef Springer J et al (2014) Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. Eur Heart J 35(14):932–941CrossRef
26.
go back to reference Thavendiranathan P, Nolan MT (2017) An emerging epidemic: cancer and heart failure. Clin Sci (Lond) 131(2):113–121CrossRef Thavendiranathan P, Nolan MT (2017) An emerging epidemic: cancer and heart failure. Clin Sci (Lond) 131(2):113–121CrossRef
27.
go back to reference Torre LA et al (2016) Global Cancer incidence and mortality rates and trends-an update. Cancer Epidemiol Biomark Prev 25(1):16–27CrossRef Torre LA et al (2016) Global Cancer incidence and mortality rates and trends-an update. Cancer Epidemiol Biomark Prev 25(1):16–27CrossRef
28.
go back to reference Voors AA et al (2017) Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. Eur J Heart Fail 19(5):627–634CrossRef Voors AA et al (2017) Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. Eur J Heart Fail 19(5):627–634CrossRef
Metadata
Title
Does heart failure increase the risk of incident cancer? A meta-analysis and systematic review
Authors
Hanlai Zhang
Yonghong Gao
Liqin Wang
Li Tian
Na An
Xinyu Yang
Xinye Li
Chao Tian
Mengchen Yuan
Xingjiang Xiong
Nian Liu
Hongcai Shang
Yanwei Xing
Publication date
01-11-2020
Publisher
Springer US
Keyword
Heart Failure
Published in
Heart Failure Reviews / Issue 6/2020
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-019-09876-0

Other articles of this Issue 6/2020

Heart Failure Reviews 6/2020 Go to the issue